SG Americas Securities LLC raised its position in shares of NuVasive, Inc. (NASDAQ:NUVA) by 68.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,919 shares of the medical device company’s stock after buying an additional 6,057 shares during the period. SG Americas Securities LLC’s holdings in NuVasive were worth $1,148,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the stock. Westside Investment Management Inc. acquired a new stake in shares of NuVasive during the first quarter worth about $109,000. FNY Partners Fund LP acquired a new stake in shares of NuVasive during the first quarter worth about $112,000. Neuburgh Advisers LLC boosted its stake in shares of NuVasive by 18.3% in the first quarter. Neuburgh Advisers LLC now owns 1,552 shares of the medical device company’s stock worth $116,000 after buying an additional 240 shares during the last quarter. Glen Harbor Capital Management LLC boosted its stake in shares of NuVasive by 18.3% in the first quarter. Glen Harbor Capital Management LLC now owns 2,134 shares of the medical device company’s stock worth $159,000 after buying an additional 330 shares during the last quarter. Finally, US Bancorp DE boosted its stake in shares of NuVasive by 1.7% in the first quarter. US Bancorp DE now owns 2,401 shares of the medical device company’s stock worth $180,000 after buying an additional 41 shares during the last quarter.

NuVasive, Inc. (NASDAQ:NUVA) opened at 62.27 on Friday. The firm’s 50-day moving average price is $68.53 and its 200 day moving average price is $73.23. The firm has a market cap of $3.16 billion, a P/E ratio of 98.06 and a beta of 1.08. NuVasive, Inc. has a 52 week low of $56.70 and a 52 week high of $81.68.

NuVasive (NASDAQ:NUVA) last issued its quarterly earnings results on Thursday, July 27th. The medical device company reported $0.46 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.02. The firm had revenue of $260.60 million during the quarter, compared to the consensus estimate of $261.95 million. NuVasive had a return on equity of 13.04% and a net margin of 3.50%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the company posted $0.40 EPS. Equities analysts forecast that NuVasive, Inc. will post $2.00 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/09/02/sg-americas-securities-llc-acquires-6057-shares-of-nuvasive-inc-nuva.html.

Several research firms recently weighed in on NUVA. Needham & Company LLC reaffirmed a “hold” rating on shares of NuVasive in a research report on Friday, July 28th. Royal Bank Of Canada upped their price objective on shares of NuVasive from $76.00 to $85.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 6th. Barclays PLC reaffirmed a “buy” rating and set a $80.00 price objective on shares of NuVasive in a research report on Wednesday, August 2nd. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $90.00 price objective on shares of NuVasive in a research report on Wednesday, August 9th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $79.00 price objective on shares of NuVasive in a research report on Sunday, July 30th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $81.18.

In other NuVasive news, EVP Peter Michael Leddy purchased 7,850 shares of the company’s stock in a transaction dated Tuesday, August 1st. The stock was purchased at an average price of $63.88 per share, for a total transaction of $501,458.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Gregory T. Lucier purchased 5,000 shares of the company’s stock in a transaction dated Thursday, August 17th. The shares were acquired at an average price of $66.22 per share, with a total value of $331,100.00. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 14,850 shares of company stock valued at $955,598. Corporate insiders own 1.20% of the company’s stock.

NuVasive Company Profile

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Institutional Ownership by Quarter for NuVasive (NASDAQ:NUVA)

Receive News & Stock Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related stocks with our FREE daily email newsletter.